Skip to main content

Pleural Disease: advances in pathology, diagnosis and therapeutic approach

Edited by:
Dr. Federico Mei, Polytechnic University of Marche, Italy 
Dr. Eihab O Bedawi, Sheffield Teaching Hospitals and the University of Sheffield, UK

Submission Status: Open   |   Submission Deadline: 10 December 2024

Respiratory Research is calling for submissions to our Collection on Pleural Disease: advances in pathology, diagnosis and therapeutic approach.

Image credit: Respiratory Unit of Dr. Federico Mei.


New Content ItemThis collection supports and amplifies research related to SDG 3: Good health and well-being

About the Collection

Respiratory Research is calling for submissions to our Collection on Pleural Disease: advances in pathology, diagnosis and therapeutic approach. 

Due to the ever growing evidence base into the mechanisms, pathogenesis and management of the myriad conditions affecting the pleural space, as well as the growth of highly specialist physician-led interventions, pleural disease is now considered a distinct and important subspecialty of respiratory medicine.

The burden of pleural disease is considerable, with pleural effusions alone estimated to affect over million people per year worldwide. The range of pleural disease is broad, including malignant and benign conditions, curative or palliative and acute or chronic, presenting as entities in themselves or as part of a wide-ranging number of other medical and surgical conditions. Pleural disease may therefore present to respiratory physicians or to many other healthcare professionals, including surgery, general internal medicine, oncology, infectious diseases and oncology hence the crucial requirement for interspecialty and multidisciplinary involvement.  Interventions such as thoracoscopy, image-guided pleural biopsy and indwelling pleural catheters play a key role in pleural specialist practice, with thoracic ultrasound being the true revolutionary tool in the pleural physician’s arsenal.

To coincide with the above, over the past decade there has been a surge in the number of major studies, many of them randomized controlled trials with patient-centered outcomes, focusing on conditions such as pneumothorax, malignant pleural effusion, mesothelioma and pleural infection. Their results have in many respects been practice changing, and provided a range of new treatment options to be offered to patients with pleural conditions. This wave of robustly designed, multicenter studies will hopefully continue over the coming years.

Despite this substantial amount of high quality data, there remain significant gaps in the literature to be addressed, such as those relating to the phenotyping and optimal treatment of pleural infection, early diagnosis of mesothelioma, the optimal palliative strategy in malignant pleural effusion as well as the pathophysiology and mechanisms underpinning the development of pleural conditions.

This collection will welcome original articles or reviews on the clinical and pre-clinical diagnosis and management of pleural diseases and we look forward to your important contributions.

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original articles or reviews. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Pleural Disease: advances in pathology, diagnosis and therapeutic approach" under the “Details” tab during the submission stage.

Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.